Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma

J Allergy Clin Immunol. 2006 Oct;118(4):809-16. doi: 10.1016/j.jaci.2006.06.036. Epub 2006 Aug 28.


Background: Recent studies suggest that there might be an association between albuterol use and worsening asthma in patients homozygous for arginine (Arg/Arg) at codon 16 of the beta-receptor. However, it is not known whether similar responses occur in Arg/Arg patients receiving long-acting beta2-agonists.

Objective: We sought to evaluate the effects of variation in the beta2-adrenergic receptor gene (ADRB2) on clinical response to salmeterol administered with fluticasone propionate.

Methods: Subjects (n = 183) currently receiving short-acting beta2-agonists were randomized to twice-daily therapy with salmeterol, 50 microg, administered with fluticasone propionate, 100 microg, in a single inhaler or daily therapy with montelukast for 12 weeks, followed by a 2- to 4-day run-out period.

Results: There was sustained and significant improvement (P < .001) over baseline in all measures of asthma control in subjects receiving salmeterol, regardless of Arg16Gly genotype. Morning peak expiratory flow in subjects with the Arg/Arg genotype showed 89.0 +/- 16.1 L/min improvement over baseline compared with 93.7 +/- 12.7 L/min for Gly/Gly subjects and 92.5 +/- 11.9 L/min for Arg/Gly subjects. Pairwise changes were similar for Arg/Arg compared with Gly/Gly or Arg/Gly genotypes (estimated differences, 4.7 L/min and 3.5 L/min, respectively). Responses did not appear to be modified by haplotype pairs. During the run-out period, all subjects had predictable and similar decreases in measures of asthma control, with no differences between genotypes.

Conclusion: Response to salmeterol does not vary between ADRB2 genotypes after chronic dosing with an inhaled corticosteroid.

Clinical implications: Analyses from this study indicate that genetic polymorphisms leading to Arg16Gly sequence changes within the beta2-adrenergic receptor do not affect patients' responses to recommended asthma therapy with salmeterol and fluticasone propionate.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acetates / administration & dosage
  • Administration, Inhalation
  • Adolescent
  • Adrenergic beta-Agonists / administration & dosage*
  • Adult
  • Aged
  • Aged, 80 and over
  • Albuterol / administration & dosage
  • Albuterol / analogs & derivatives*
  • Androstadienes / administration & dosage
  • Anti-Asthmatic Agents / administration & dosage
  • Asthma / drug therapy*
  • Asthma / genetics*
  • Cyclopropanes
  • Drug Therapy, Combination
  • Female
  • Fluticasone
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Quinolines / administration & dosage
  • Receptors, Adrenergic, beta-2 / genetics*
  • Respiratory Function Tests
  • Salmeterol Xinafoate
  • Sulfides


  • Acetates
  • Adrenergic beta-Agonists
  • Androstadienes
  • Anti-Asthmatic Agents
  • Cyclopropanes
  • Quinolines
  • Receptors, Adrenergic, beta-2
  • Sulfides
  • Salmeterol Xinafoate
  • Fluticasone
  • montelukast
  • Albuterol